<DOC>
	<DOC>NCT02210663</DOC>
	<brief_summary>This is a Phase 1 study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of single agent Veliparib in Japanese subjects with advanced solid tumors.</brief_summary>
	<brief_title>A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Veliparib</mesh_term>
	<criteria>Histologically or cytologically confirmed malignant solid tumor, and any of the following: * Subjects with recurrent high grade serous ovarian cancer who completed or discontinued platinum based therapy; * Subjects with BRCAmutated breast cancer who have received prior chemotherapy with anthracycline and/or taxanes; * Subjects with deleterious mutations of BRCA with advanced solid tumors who have received available standard therapies. Eastern Cooperative Oncology Group (ECOG) performance status of 01. Life expectancy of greater than 12 weeks. Adequate organ and marrow functionÂ· Measurable or nonmeasurable disease. Major surgery and/or radiation within (&lt;) 4 weeks prior to study enrollment. Chemotherapy or hormone therapy within (&lt;) 4 weeks prior to study enrollment except for mitomycin C and nitrosoureas, in which case it is 6 weeks. Any investigational agents within (&lt;) 4 weeks prior to study enrollment. Any anticancer Chinese medicine/herbal remedies within 14 days prior to study enrollment. Toxicities (with the exception of alopecia) from prior major surgery, radiation, or systemic chemotherapy have not recovered to less than grade 2.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>PARP</keyword>
	<keyword>Primary peritoneal cancer</keyword>
	<keyword>Fallopian tube</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>veliparib</keyword>
	<keyword>ABT-888</keyword>
	<keyword>BRCA</keyword>
</DOC>